 |
|
|
| |
Short duration sofosbuvir-velpatasvir is inferior to standard duration therapy in the treatment of recently acquired HCV infection:
results from the REACT study
|
| |
| |
AASLD 2019 Nov 8-12 Boston
Reported by Jules Levin
Matthews GV1,2, Bhagani S3, Van der Valk M4, Rockstroh JK5, Kim A6, Thurnheer C7, Feld JJ8, Bruneau J9, Gane E10, Hellard M11, Grebely J1, Applegate T1, Marks P1, Martinello M1, Petoumenos K1, Dore GJ1,2 on behalf of the REACT study group.
1The Kirby Institute, University of New South Wales, Australia, 2St Vincent's Hospital, Sydney Australia, 3Royal Free Hospital, London, UK; 4Academic Medical Centre, Amsterdam, The Netherlands,5University of Bonn, Bonn, Germany;6 Massachusetts General Hospital, Boston, USA; 7 Bern University, Bern, Switzerland; 8Toronto General Hospital, Toronto, Canada; 9CHUM, Montreal, Canada,10 Auckland Hospital, Auckland, New Zealand; 11The Alfred Hospital, Melbourne, Australia
Acknowledgements:
The Kirby Institute is affiliated with the Faculty of Medicine, University of New South Wales. The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. Study drug was supplied by Gilead Sciences. The content is solely the responsibility of the authors. The REACT team acknowledges and thanks all study investigators, site research staff, central co-ordinating team, the DSMB and the patients who participated.
|
| |
|
|
|
|
|
